NCT00093314View on ClinicalTrials.gov

HuMax-CD20 in Chronic Lymphocytic Leukemia

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

HuMax-CD20

Trial Locations (1)

52242

University of Iowa, Hospitals and Clinics, Iowa City

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00093314 - HuMax-CD20 in Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter